Bristol-Myers Squibb Co (NYSE:BMY) – Investment analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a report released on Tuesday. Jefferies Group analyst J. Holford now anticipates that the biopharmaceutical company will post earnings per share of $2.99 for the year, up from their previous estimate of $2.98. Jefferies Group has a “Hold” rating and a $72.00 price objective on the stock. Jefferies Group also issued estimates for Bristol-Myers Squibb’s FY2021 earnings at $4.99 EPS.

BMY has been the topic of a number of other reports. UBS Group reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a research note on Monday, October 9th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Finally, Citigroup raised their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $65.11.

Bristol-Myers Squibb (NYSE BMY) opened at $61.85 on Thursday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a 12 month low of $46.01 and a 12 month high of $66.10. The firm has a market cap of $101,230.00, a P/E ratio of 24.35, a price-to-earnings-growth ratio of 2.20 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.77 earnings per share.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend is Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is presently 62.99%.

In other news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. First Hawaiian Bank increased its holdings in Bristol-Myers Squibb by 5.5% in the 2nd quarter. First Hawaiian Bank now owns 6,283 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 330 shares during the last quarter. Perkins Coie Trust Co increased its holdings in Bristol-Myers Squibb by 33.6% in the 2nd quarter. Perkins Coie Trust Co now owns 3,084 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 775 shares during the last quarter. City Holding Co. increased its holdings in Bristol-Myers Squibb by 23.6% in the 2nd quarter. City Holding Co. now owns 40,390 shares of the biopharmaceutical company’s stock valued at $2,251,000 after purchasing an additional 7,705 shares during the last quarter. Koshinski Asset Management Inc. increased its holdings in Bristol-Myers Squibb by 46.6% in the 2nd quarter. Koshinski Asset Management Inc. now owns 8,869 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 2,820 shares during the last quarter. Finally, Dynamic Advisors Solutions LLC increased its holdings in Bristol-Myers Squibb by 126.3% in the 2nd quarter. Dynamic Advisors Solutions LLC now owns 17,365 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 9,690 shares during the last quarter. 69.74% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/18/fy2017-earnings-forecast-for-bristol-myers-squibb-co-bmy-issued-by-jefferies-group.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.